<DOC>
	<DOCNO>NCT00004177</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Peripheral stem cell transplantation may able replace immune cell destroy therapy use kill tumor cell . PURPOSE : Phase I/II trial study effectiveness radiolabeled monoclonal antibody plus peripheral stem cell transplantation treat patient refractory recurrent ovarian epithelial cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation Treating Patients With Refractory Recurrent Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine normal organ tumor dosimetry yttrium Y 90 monoclonal antibody MN-14 use indium In 111 monoclonal antibody MN-14 pretherapy patient advance ovarian epithelial cancer . II . Evaluate extent duration antitumor response patient regimen . OUTLINE : This dose escalation study yttrium Y 90 monoclonal antibody MN-14 ( 90Y hMN-14 ) . Patients receive filgrastim ( G-CSF ) subcutaneously ( SQ ) day -17 -13 , follow leukapheresis day -14 -12 . If adequate number CD34+ cell harvest , bone marrow also collect . Patients receive pretherapy target consist indium In 111 monoclonal antibody MN-14 30 minute day -7 . At least 1 confirmed tumor site must target . Patients receive 90Y hMN-14 IV 30-45 minute day 0 . PBSC reinfused within 7 14 day 90 hMN-14 administration . Patients receive G-CSF SQ IV blood count recover . Cohorts 3-6 patient receive escalate dos 90Y hMN-14 maximum tolerate dose ( MTD ) determine . The MTD define either dose 1 6 patient experience dose limit toxicity threshold radiation dose lung , kidney , liver reach . Patients follow weekly 1 month , every 2 week 2 month , monthly 3 month , every 3 month 2 year , every 6 month 5 year . PROJECTED ACCRUAL : Approximately 48-51 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically refractory recurrent ovarian epithelial cancer Resistant platinum taxane contain chemotherapy within past 6 month Autologous peripheral blood stem cell ( PBSC ) bone marrow available At least 1 measurable site confirm CT target pretherapy indium In 111 monoclonal antibody MN14 image No bone marrow involvement PATIENT CHARACTERISTICS : Age : 18 80 Performance status : Karnofsky 70100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL SGOT le 2.0 time upper limit normal ( ULN ) Renal : Creatinine le 1.5 time ULN Creatinine clearance least 50 mL/min Cardiovascular : LVEF least 50 % MUGA Pulmonary : FVC , FEV1 , DLCO least 70 % predict Other : Not pregnant Fertile patient must use effective contraception 3 month study No AIDSrelated illness No concurrent significant medical complication would preclude compliance No severe anorexia , nausea , vomit No history allergy antibody 90Y hMN14 PRIOR CONCURRENT THERAPY : Biologic therapy : No prior imaging study murine monoclonal antibody show reactivity yttrium Y 90 monoclonal antibody MN14 ( 90Y hMN14 ) Chemotherapy : At least 4 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy index lesion recover No prior radiotherapy great 25 % red marrow No prior radiotherapy maximum tolerated level critical organ ( e.g. , lung , liver , kidney ) Surgery : At least 4 week since prior major surgery Other : No concurrent antiretroviral medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>